SCHEMBL4520097

SCHEMBL4520097

COCCNC(=O)c1cccc(/C=C/C(=O)c2c(O)c3cccnc3n(C)c2=O)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PADI4 Q9UM07 2/20 0.40
KDM4E B2RXH2 6/20 0.38
CNR2 P34972 3/20 0.38
ALDH1A1 P00352 6/20 0.37
HPGD P15428 5/20 0.37
HSD17B10 Q99714 2/20 0.37
HTT P42858 2/20 0.37
CNR1 P21554 2/20 0.36
TP53 P04637 3/20 0.36
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
LMNA P02545 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
NLRP3 Q96P20 1/20 0.36
MAPT P10636 3/20 0.35
USP2 O75604 2/20 0.35
XBP1 P17861 1/20 0.35
HTR3E A5X5Y0 1/20 0.35
HTR3B O95264 1/20 0.35
HTR3A P46098 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4520101 1.00 PADI4 (0.40) PADI4KDM4ECNR2ALDH1A1HPGD
SCHEMBL13818105 0.92 KDM4E (0.46) PADI4KDM4ECNR2ALDH1A1HPGD
SCHEMBL13818103 0.91 PADI4 (0.40) PADI4KDM4ECNR2ALDH1A1HPGD
SCHEMBL13818113 0.90 PADI4 (0.40) PADI4KDM4ECNR2ALDH1A1HPGD
SCHEMBL13818106 0.90 PADI4 (0.40) PADI4KDM4ECNR2ALDH1A1HPGD
SCHEMBL13818111 0.88 EGLN1 (0.45) PADI4KDM4ECNR2ALDH1A1HPGD
SCHEMBL4510491 0.83 KDM4E (0.39) KDM4ECNR2ALDH1A1HPGDHSD17B10
SCHEMBL4510487 0.83 KDM4E (0.39) KDM4ECNR2ALDH1A1HPGDHSD17B10
SCHEMBL13818097 0.83 PADI4 (0.40) PADI4KDM4EALDH1A1HPGDTP53
SCHEMBL3495386 0.82 KDM4E (0.42) KDM4ECNR2ALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143368-A1 Use of Cinnamoyl Compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-06-04 US disclosed
US-20090143368-A1 Use of Cinnamoyl Compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-06-04 US disclosed
US-20090143368-A1 Use of Cinnamoyl Compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-06-04 US disclosed
EP-1857104-A1 USE OF CINNAMOYL COMPOUND Sumitomo Chemical Company, Limited (JP) 2007-11-21 EP disclosed
EP-1857104-A1 USE OF CINNAMOYL COMPOUND Sumitomo Chemical Company, Limited (JP) 2007-11-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143368-A1 Use of Cinnamoyl Compound COL2A1, COL1A1, SMAD2 PADI4 4647/4885KDM4E 1537/4885CNR2 2699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.